ClinicalTrials.gg
RecruitingNCT06823167Updated Aug 10, 2026

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

A Phase 1 interventional study of IM-1021 in Solid Malignancies and Hematologic Malignancies, sponsored by Immunome, Inc.. Recruiting at 24 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Immunome, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
190
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 821 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 276 under way, 12 of them phase 3. Hematologic Neoplasms · United States.

Planned enrollment
86th of 658
190 · median 40
Started
2025
with 32 others
Phase 1
195 of 821
35 open now
Primary completion
2028-05
later than 180 of 273 live
Registered
765th of 821
by date

Among the 821 studies in Hematologic Neoplasms with a site in United States, this one is the 86th largest by planned enrollment of the 658 interventional ones that give a count, is one of 33 that started in 2025, is one of 195 in phase 1, reaches primary completion later than 180 of the 273 other live ones, and was the 765th registered.

Hematologic Neoplasms

1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

181 of the 821 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

176 more — sign in →

All 181 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 821 studies in Hematologic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.

Read the detailed description

IM-1021-101 is a 2-part Phase 1 first-in-human, open-label, multicenter dose escalation and expansion study designed to determine the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of the ROR1 directed antibody-drug conjugate (ADC) IM-1021. IM-1021 will be administered to participants with advanced B-cell lymphomas and advanced solid tumors. Part A of the study is a dose escalation phase to evaluate safety and tolerability of IM-1021 and to determine recommended doses for further development. IM-1021 will be administered intravenously on an intermittent basis. The safety and tolerability of escalating doses of IM-1021 will be evaluated. Alternative dosing schedules may also be evaluated. Part B of the study is an expansion phase to further evaluate safety and tolerability of IM-1021 at candidate recommended doses in indication specific cohorts of participants. The safety and preliminary efficacy endpoints of this study will inform a preliminary risk-benefit assessment of IM-1021 in this patient population.

03

Conditions studied

  • Solid Malignancies
  • Hematologic Malignancies
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. signed by the participant prior to conducting study-specific procedures
  2. ≥18 years of age
  3. (ECOG) performance status of 0, 1, or 2
  4. Histological or cytological diagnosis of:

    Part A: advanced B-cell lymphomas or solid tumors, of the following subtypes:

    B-cell Lymphomas:

    • Mantle cell lymphoma (MCL)
    • Diffuse large B-cell lymphoma (DLBCL) (including Richter's transformation)
    • Follicular lymphoma
    • Small lymphocytic lymphoma (SLL)
    • Marginal zone lymphoma

    Solid Tumors:

    • Pancreatic cancer
    • Non-squamous non-small cell lung cancer (NSCLC)
    • Malignant mesothelioma
    • Epithelial ovarian cancer. Participants with fallopian tube and/or peritoneal are also eligible.
    • Triple-negative breast cancer.
    • Liposarcoma

    Other, unlisted histologies, if approved by the Sponsor Medical Monitor

    Part B Cohorts B1, B2, and B3:

    Histological or cytological diagnosis of the cohort-specific disease indication. Indications may include those listed in Inclusion Criterion 4.a

  5. Participants must have adequate organ function.
  6. Participants must have a negative pregnancy test, be willing to practice highly effective methods of , use condoms, and refrain from oocyte/sperm donation, as applicable, as detailed in the protocol.
  7. Participants must have disease and have received all approved and available therapeutic options.
  8. Participants must have as per the relevant response assessment framework: Lugano Classification for lymphoma (except SLL), per iwCLL criteria for SLL , and per v.1.1 for solid tumors.

Exclusion criteria

Exclusion Criteria:

  1. Previously treated with an ADC with a topoisomerase-1 inhibitor payload, except: Participants with triple negative breast cancer may have received up to one prior ADC with a topoisomerase-1 inhibitor payload.
  2. Previously received a ROR1-targeted therapy (eg, ADC, cell therapy, or monoclonal antibody).
  3. History of an anaphylactic reaction to irinotecan or ≥ grade 3 GI toxicity to prior irinotecan.
  4. \< 12 weeks.
  5. Prior solid organ transplant.
  6. Participants with symptomatic ascites or pleural effusion. Participants who are clinically stable for at least 2 weeks following treatment for these conditions (including therapeutic thoraco- or paracentesis or catheter) are eligible.
  7. For participants with known active central nervous system (CNS) disease

    1. For participants with solid tumors: Participant has a known active CNS primary tumor or and/or carcinomatous meningitis. Participants with previously treated may participate provided they are clinically stable for at least 4 weeks prior to study entry, have no radiological evidence of new or enlarging brain metastases, and are off or on a stable dose up to an equivalent of prednisone 10 mg/day for at least 15 days prior to first dose of study medication. Participants who have symptoms consistent with CNS metastasis must have a negative magnetic resonance imaging (MRI) or other clinically appropriate imaging study if the participant is not able to undergo contrast-enhanced MRI and approved by the Sponsor Medical Monitor during the screening period.
    2. For participants with lymphoma: Participant has active cerebral/meningeal disease related to the underlying . Participants with a history of cerebral/meningeal disease related to the underlying malignancy are allowed if prior CNS disease has been effectively treated and without progression for at least 3 months.
  8. Participant has a known history of malignant primary brain tumor, or another primary solid or hematologic malignancy (other than that under study), unless the participant has undergone potentially curative therapy with no evidence of that disease for at least 2 years. Exception: The time requirement does not apply to participants who underwent successful definitive resection of certain cancers.
  9. Participant has certain other significant medical conditions including cardiac, pulmonary, and infectious disease as detailed in the protocol.
  10. Participant is pregnant, breastfeeding, or expecting to conceive within the projected duration of the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
190 participants (estimated)

Study arms

  • Experimental
    Part A: IM-1021 Dose Escalation

    IM-1021 given into the vein (IV; intravenously)

    Drug: IM-1021

  • Experimental
    Part B: IM-1021 Monotherapy Dose Expansion

    IM-1021 given into the vein (IV; intravenously)

    Drug: IM-1021

Interventions

  • DrugIM-1021

    IM-1021 is an antibody-drug conjugate

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of IM-1021 in participants with advanced lymphomas and advanced solid tumors as measured by incidence of treatment emergent adverse events (TEAEs)

    Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 5.0, including serious adverse events (SAEs), AEs of interest (AEI), AEs leading to discontinuation, and deaths

    Time frame: From first dose to 37 days following last dose of study treatment

  2. Determine the recommended dose(s) and schedule(s) of IM-1021 for further development

    Type, frequency, seriousness, and severity of AEs graded using the NCI-CTCAE v6.0, including SAEs, AEIs, AEs leading to discontinuation, and deaths

    Time frame: From first dose to 37 days following last dose of study treatment

Secondary outcomes

  1. Area under the concentration-time curve (AUC) of IM-1021 in participants with advanced lymphomas and advanced solid tumors

    Pharmacokinetic (PK) parameter

    Time frame: Through 30-37 days following last dose of IM-1021 up to end of study

  2. Concentration at end of infusion (Ceoi) of IM-1021 in participants with advanced lymphomas and advanced solid tumors

    PK parameter

    Time frame: Through 30-37 days following last dose of IM-1021 up to end of study

  3. Maximum observed concentration (Cmax) of IM-1021 in participants with advanced lymphomas and advanced solid tumors

    PK parameter

    Time frame: Through 30-37 days following last dose of IM-1021 up to end of study

  4. Time to maximum observed concentration (Tmax) of IM-1021 in participants with advanced lymphomas and advanced solid tumors

    PK parameter

    Time frame: Through 30-37 days following last dose of IM-1021 up to end of study

  5. Trough Concentration of IM-1021 in participants with advanced lymphomas and advanced solid tumors

    PK parameter

    Time frame: Through 30-37 days following last dose of IM-1021 up to end of study

  6. Apparent Terminal Half-Life (t1/2) of IM-1021 in participants with advanced lymphomas and advanced solid tumors

    PK parameter

    Time frame: Through 30-37 days following last dose of IM-1021 up to end of study

  7. Characterize the immunogenicity of IM-1021

    Determined by the incidence of anti-drug antibodies (ADA) to IM-1021 from pre-infusion sample prior to each cycle.

    Time frame: From first dose to about 30 days following last dose of study treatment

  8. To evaluate the preliminary anti-tumor activity of IM-1021 in participants with advanced lymphomas and advanced solid tumors

    Objective response rate (ORR) as measured by Lugano Classification for participants with lymphoma (except small lymphocytic lymphoma \[SLL\]), per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for participants with SLL, and per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 for participants with solid tumors

    Time frame: Week 6 until disease progression or participant discontinuation from study

  9. To evaluate the preliminary anti-tumor activity of IM-1021 in participants with advanced lymphomas and advanced solid tumors

    Complete response rate (CRR) as measured by Lugano Classification for participants with lymphoma (except SLL), per iwCLL criteria for participants with SLL, and per RECIST v.1.1 for participants with solid tumors

    Time frame: Week 6 until disease progression or participant discontinuation from study

  10. To evaluate the preliminary anti-tumor activity of IM-1021 in participants with advanced lymphomas and advanced solid tumors

    Disease control rate (DCR) as measured by Lugano Classification for participants with lymphoma (except SLL), per iwCLL criteria for participants with SLL, and per RECIST v.1.1 for participants with solid tumors

    Time frame: Week 6 until disease progression or participant discontinuation from study

07

Study locations

24 of 24 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for May 2028, 39 months after the start.

Of 95 industry-sponsored phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 78. This study's planned 39 months is close to that.

Counting every sponsor, half of 159 studies reached it within 51 months; a quarter within 28 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2025
First posted
Feb 12, 2025
StartActual
Feb 26, 2025
Primary completionEst.
May 2028
CompletionEst.
Feb 2029
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06823167
Lead sponsor
Immunome, Inc.
Responsible party
Sponsor
First posted
Feb 12, 2025
Start date
Feb 26, 2025
Primary completion
May 2028 (estimated)
Completion
Feb 2029 (estimated)
Last update
Aug 10, 2026

Study contacts

Immunome Medical Monitor
Contact
info@immunome.com
425.939.7410

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion